Moleculin Biotech (MBRX) Prices 14.27M Share Common Offering at $4.75/Sh

Moleculin Biotech (MBRX) Announces Proposed Underwritten Public Offering

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it intends to offer and sell shares of common stock (or pre-funded warrants... More

Moleculin Biotech (MBRX) Surges 45% on Early Data

Moleculin Biotech (NASDAQ: MBRX) surges 45% announces 100% survival in Osteosarcoma Lung Metastases animal model.

Moleculin Biotech (MBRX) Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. This appears to be the result of the high cytotoxic potential of Annamycin previously demonstrated in vitro against sarcoma cells in combination with its high uptake by the lungs where the tumors in this study are localized. Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited... More

Moleculin Biotech (MBRX) PT Raised to $29 at Roth Capital, Adjusting PT After 1 To 6 Stock Split

Roth Capital analyst Jonathan Aschoff raised the price target on Moleculin Biotech (NASDAQ: MBRX) to $29.00 (from $5.00) while maintaining a Buy rating.

Moleculin Biotech (MBRX) Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has signed an agreement with Catalyst Clinical Research (Catalyst), a contract research organization, to manage its US clinical trial to study the ability of Annamycin to treat soft tissue sarcoma (STS) that has metastasized to the lungs.

Soft tissue sarcomas are the most common form of sarcoma, accounting for an estimated... More